Verona Pharma (VRNA)

Executive Summary

Verona Pharma is a biopharmaceutical company focused on developing innovative therapies for chronic respiratory diseases. Its lead product, ensifentrine (Ohtuvayre), a first-in-class PDE3/4 inhibitor, received FDA approval in June 2024 for the maintenance treatment of COPD, marking a significant milestone. The company is now transitioning to a commercial-stage entity, with initial sales performance indicating strong uptake. Beyond COPD, Verona is pursuing clinical development in asthma and cystic fibrosis, leveraging ensifentrine's dual mechanism of action. With a robust cash position and expanding pipeline, Verona Pharma is well-positioned to address substantial unmet needs in respiratory care. Key risks include competitive dynamics and reliance on a single approved product.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for ensifentrine in asthma65% success
• Q2 2026Q2 2026 earnings report with commercial update100% success
• TBDPotential label expansion for ensifentrine in COPD combination therapy70% success